Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.
about
A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial)Dopamine transporter imaging for the diagnosis of dementia with Lewy bodiesOpioids for agitation in dementiaWithdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementiaDopamine transporter imaging for the diagnosis of dementia with Lewy bodiesOpioids for agitation in dementiaAntidepressants for agitation and psychosis in dementiaAntidepressants for agitation and psychosis in dementiaCannabinoids for the treatment of dementiaCannabinoids for the treatment of dementiaAtypical antipsychotics for aggression and psychosis in Alzheimer's diseaseNonpharmacologic management of behavioral symptoms in dementiaQuetiapine in the treatment of psychosis in Parkinson's diseaseUsing C. elegans to discover therapeutic compounds for ageing-associated neurodegenerative diseasesDementiaRandomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternativesChallenge of changing nursing home prescribing culturePharmacological and nonpharmacological management of delirium in critically ill patients.The BEHAVE-AD assessment system: a perspective, a commentary on new findings, and a historical reviewPharmacological management of behavioral symptoms associated with dementiaCLINICAL PRACTICE. Advanced DementiaSeptic encephalopathy: when cytokines interact with acetylcholine in the brainAssessment and management of behavioral and psychological symptoms of dementiaDrug treatment in older people before and after the transition to a multi-dose drug dispensing system--a longitudinal analysisDifferential impact of two risk communications on antipsychotic prescribing to people with dementia in Scotland: segmented regression time series analysis 2001-2011Weight Loss in Patients with Dementia: Considering the Potential Impact of Pharmacotherapy.Can systematic reviews contribute to regulatory decisions?Non-pharmacological treatment reducing not only behavioral symptoms, but also psychotic symptoms of older adults with dementia: a prospective cohort study in Taiwan.Dealing with behavioral and psychological symptoms of dementia: a general overview.The effect of folk recreation program in improving symptoms: a study of Chinese elder dementia patients.Predictors of non-pharmacological intervention effect on cognitive function and behavioral and psychological symptoms of older people with dementia.Dementia.Continuous use of antipsychotics and its association with mortality and hospitalization in institutionalized Chinese older adults: an 18-month prospective cohort study.The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's diseaseDopamine D2 receptor antagonism suppresses tau aggregation and neurotoxicityMortality in schizophrenia and related psychoses: data from two cohorts, 1875-1924 and 1994-2010Clinical Characteristics of Patients with Late Life Bipolar Disorder in the Community: Data from the NNDC Registry.Comparative cardiovascular safety of dementia medications: a cross-national study.Antipsychotics and cognitive decline in Alzheimer's disease: the LASER-Alzheimer's disease longitudinal study.Psychotropic medication use among nursing home residents in Austria: a cross-sectional study.
P2860
Q21144654-51E576DC-1A80-45F8-A5D1-4FB704F32103Q24186395-543EA1C4-E56D-4E70-B898-991DF927E6EEQ24187950-E2753994-9D0F-4B0B-B429-3386ECC3FF96Q24198248-44EA5FC8-A901-49F1-A2D5-F76EF8E4843DQ24201437-E0DDDBC0-6AAC-42BB-9DE4-363967668591Q24201556-9F2B2634-26B4-4898-9FE0-9AF78E2CDC7DQ24236550-61AFD756-E75B-4D25-9AB3-31BA2E311171Q24241426-CA6A6447-E03E-461B-8325-C4A0BDF548B0Q24241582-C3A9BF1D-A41C-4982-9FA1-C15A24B30D3CQ24242873-6610B87E-5A25-4BFD-9955-6BC194EE77EFQ24244504-3A72BA50-B0EF-4146-AD81-014B3FD96490Q24598981-682323D5-30AD-48A3-8D8A-1D51BD8432A6Q24628941-B45D555B-AE2A-448D-9F47-84E63293CCA5Q26776093-8BFEBB9C-46B5-455B-9E9A-8EEF378FE341Q26860881-C23545E8-9492-4D7E-B60E-865184DCDE7CQ26863435-243E9A3B-CB17-41AD-BBE0-A72B6B529231Q26865397-52AE32FE-0752-45EB-9747-C61D320992A5Q27005223-B20FA9BA-DA7D-42C0-BB33-569DE4D1EC30Q27022753-52977DF7-10D5-4332-8360-7C57ECFFFAFFQ28081955-85CC9BD7-6613-4C99-88E6-6F0D40F0BC5CQ28082593-70B451D7-09F9-4F76-AA8E-526281025F79Q28082616-8ED51006-A453-4ACF-903B-E448F3CC43E2Q28088782-3B81B6DF-2818-49A4-8897-8255B19A6523Q28534192-C11BFD9A-ADA5-4A7F-8A46-CA23340D9EF0Q28534696-942B99F0-7016-42E9-80AA-778BA85ECB4CQ30234535-95CB0C6B-3661-4922-AD8E-3C69291139FDQ30239767-F96E2E96-FCB0-4C77-966C-FDA03657ACBDQ30352567-3F499A53-CA91-4D70-8A29-465666330E00Q30376652-F394DAC1-AB1B-4556-9896-0A94442155D4Q30389787-0CFD82D3-8C62-4B88-BA5E-A06B61E5BD10Q30401309-DF52EB51-B501-4413-8F92-FFDF207FB97DQ30404451-90DB5386-6721-4618-8277-66DD8C1FA867Q30406882-89DE3E54-D828-45F8-A8D9-45075070CD93Q30413790-BF0CD798-CA59-4E19-B778-797AF4A90F84Q30535414-395A5936-7B52-487E-A384-79363A826A43Q30572656-386DF0C7-D120-46B9-9E48-A5463117F2AEQ30891260-FBD19AAD-E9E5-4210-BA89-BC1476ED862BQ33162060-1A03BC22-5E41-41AE-8A10-91206DAE7CDCQ33248004-3C5A76C4-D286-40A9-ADBC-EEF0C438887CQ33449888-CEB80A6D-86D0-4C7C-98F9-8EBBB7AA9302
P2860
Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Risk of death with atypical an ...... zed placebo-controlled trials.
@ast
Risk of death with atypical an ...... zed placebo-controlled trials.
@en
Risk of death with atypical an ...... zed placebo-controlled trials.
@nl
type
label
Risk of death with atypical an ...... zed placebo-controlled trials.
@ast
Risk of death with atypical an ...... zed placebo-controlled trials.
@en
Risk of death with atypical an ...... zed placebo-controlled trials.
@nl
prefLabel
Risk of death with atypical an ...... zed placebo-controlled trials.
@ast
Risk of death with atypical an ...... zed placebo-controlled trials.
@en
Risk of death with atypical an ...... zed placebo-controlled trials.
@nl
P2093
P921
P356
P1476
Risk of death with atypical an ...... zed placebo-controlled trials.
@en
P2093
Karen S Dagerman
Lon S Schneider
Philip Insel
P304
P356
10.1001/JAMA.294.15.1934
P407
P577
2005-10-01T00:00:00Z